在白风治疗中使用口服JAK抑制剂
Angeliki Panagopoulou1, Elena Sotiriou1, Ilias Papadimitriou1
1First Department of Dermatology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dermatology and therapy
|January 20, 2026
概括
口服雅努斯激酶 (JAK) 抑制剂对治疗白风,一种影响生活质量的皮肤色素障碍有前途. 需要进一步的研究来确定这种情况的最终治疗方案.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- Vitiligo 是一种色素丧失障碍,影响全球人口的0.5-2%.
- 黑色素细胞功能受损导致明显的白色皮肤斑块.
- Vitiligo 严重影响患者的生活质量,造成心理困扰和社会耻辱.
研究的目的:
- 审查和综合口服氏激酶 (JAK) 抑制剂治疗白风的现有证据.
- 巩固各种研究设计关于JAK抑制剂疗效和安全性的研究结果.
主要方法:
- 在PubMed,Medline和Embase数据库中进行了系统的文献搜索.
- 搜索重点是到2025年4月发表的关于治疗白风的口服JAK抑制剂的研究.
主要成果:
- 确定了217篇文章,详细介绍了JAK抑制剂的使用,包括巴里西提尼布,托法西提尼布,乌帕达西提尼布,里特莱西提尼布,鲁克索利提尼布,普雷博西提尼布和povorcitinib.
- 识别的文献包括观察性研究,案例报告,案例系列,试点研究,评论和元分析.
结论:
- 口服JAK抑制剂代表了白风管理的潜在治疗途径.
- 进一步的严格,长期和受控的研究对于建立最佳治疗方案和确认安全性和有效性至关重要.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
535
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
535
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
577
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
577
The JAK-STAT Signaling Pathway
12.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.2K
Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
Oral Cavity
3.0K
The oral cavity, or the mouth, is a complex structure in humans that plays a vital role in our day-to-day lives. Its role is not only in chewing and swallowing food; it also plays a role in speech and facial expressions.
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
3.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
462
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
462


